- Molecular NameMeperidine
- SynonymNA
- Weight247.338
- Drugbank_IDDB00454
- ACS_NO57-42-1
- Show 3D model
- LogP (experiment)2.45
- LogP (predicted, AB/LogP v2.0)2.4
- pka8.7
- LogD (pH=7, predicted)0.8
- Solubility (experiment)3.22 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-1.01
- LogSw (predicted, AB/LogsW2.0)3.4
- Sw (mg/ml) (predicted, ACD/Labs)3.12
- No.of HBond Donors0
- No.of HBond Acceptors3
- No.of Rotatable Bonds4
- TPSA29.54
- StatusFDA approved
- Administrationoral, IV, IM, insufflated, rectal
- PharmacologyA fast-acting opioid analgesic drug.
- Absorption_value100.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability52.0
- Protein binding70.0
- Volume of distribution (VD)4.4 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmMeperidine undergoes P450-dependent N-demethylation to normeperidine. Metabolite is not an analgesic but is a potent CNS-excitatory agent and is associated with adverse side effects of meperidine.
- Half life3.2 h
- ExcretionRenal
- Urinary Excretion5
- Clerance17 ml/min/kg
- ToxicityThe major hazards of meperidine, as with other narcotic analgesics, are respiratory depression and, to a lesser degree, circulatory depression; respiratory arrest, shock, and cardiac arrest have occurred. The most frequently observed adverse reactions include lightheadedness, dizziness, sedation, nausea, vomiting, and sweating. These effects seem to be more prominent in ambulatory patients and in those who are not experiencing severe pain. In such individuals, lower doses are advisable. Some adverse reactions in ambulatory patients may be alleviated if the patient lies down.
- LD50 (rat)LD50=170
- LD50 (mouse)LD50=178